AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms
This trial is an ongoing single-center, pragmatic, parallel-group randomized controlled superiority trial currently in participant recruiting phase, conducted within intensive care unit teaching wards at Peking Union Medical College Hospital, Beijing, China. The scheduled trial implementation period spans March 2026 to June 2026, aiming to evaluate whether an institution-specific, protocol-bound retrieval-augmented AI educational agent (named ICU-Tutor) can reduce residents' extraneous cognitive load and improve standardized ICU protocol task performance compared with free access to unrestricted commercial general-purpose large language model AI tools during early ICU clinical rotation. The trial plans to screen a total of 44 first-time ICU rotating resident candidates, with pre-defined exclusion standards to eliminate unqualified individuals; approximately 44 eligible residents will un
Sign in to get the eligibility rules as simple questions to take to your doctor.
AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy